Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien
The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe
On March 17th, the State Council's joint prevention and control mechanism held a press conferenc
2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibito
Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide
Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related pepti
Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22